MOTS-c
Mouse data only; no published human trial.
A small peptide encoded in . In mice it improves how muscle handles sugar and mimics some effects of exercise. No human trial of MOTS-c itself has been published. A , also called Mitochondrial ORF of the 12S rRNA type-c.
What the evidence shows
Side effects and risks
Who should avoid it: Athletes, and anyone who wants to know what they are injecting.
Athletes: Prohibited at all times (class S4). Added to hormone and metabolic modulators from 2024. Experimental and not approved for human use. USADA advisory on 2024 WADA list, 2023-10
How it works
- Where it acts
- Thought to act on AMPK, the energy sensor inside cells, mainly in muscle.
- What it changes
- In mice, better handling of blood sugar and more exercise capacity.
- What people notice
- No published human trial, so effects in people are unknown.
How it has been given in studies
No established human dose. The only human data are for the related compound CB4211, 25 mg injected daily for four weeks.
Getting it in the United States
The legal route for MOTS-c
Not FDA-approved. FDA advisers have reviewed, or are due to review, whether pharmacies may compound it. Until FDA acts, there is no lawful route. Vials sold for research use are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Online research-use-only sellers
Sold on many websites labelled for research purposes only and promoted by influencers as an injectable for weight loss and bodybuilding. No approved product exists, so contents and safe use are unknown.
Compounding pharmacies via clinics
A 2026 advisory vote favoured compounding, but until the FDA finishes rulemaking MOTS-c fits no lawful compounding category. Some states, such as Ohio, say it cannot be compounded. Clinics that advertise it face federal and state liability.
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- More stamina in the gym
- Feeling of more energy
Reported problems
- Itchy welts at the injection site
- No change
- Cost
Energy and stamina are among the easiest effects to imagine, and there is no placebo-controlled human data to check them against.
More contextWhat public figures say, videos and articles, when options run out and the chemistry
What experts and influencers say
Paraphrased from the linked sources.
Told Medscape, as summarised by USC, that peptide use is popular without rigorous evidence. Said he would advise against FDA deregulation of MOTS-c now and would call for funding and faster clinical trials.
Source: USC Leonard Davis School summary of Medscape, May 2026
Pinchas CohenWebsiteMixed view
Photo source: eurekalert.org
Warns athletes that MOTS-c is banned at all times as a metabolic modulator, has no completed human trials, and that online buyers report palpitations, insomnia, fever and injection site irritation.
US Anti-Doping AgencySourceWarns against
Has promised to end what he calls the FDA's war on peptides and has called himself a big fan. In February 2026 he said the FDA planned to move about 14 experimental peptides back to compounding pharmacies.
Robert F. Kennedy Jr.InstagramRecommends
Voted 7 to 5 with 2 abstentions to recommend allowing pharmacies to compound MOTS-c. FDA scientists had advised against it, citing too little safety, efficacy and characterization data.
Argued the first question for FDA is whether these peptides have been shown safe and effective, not how much demand exists.
Source: Bloomberg Law, Jul 2026
Photo source: home.ecri.org
Ahead of the July 2026 FDA advisory meeting, said his group wants guard rails so peptides can be compounded lawfully.
Source: Bloomberg Law, Jul 2026
Lee RosebushWebsiteRecommends
Photo source: pepmed.org
Cautioned that leaving the restricted category did not make MOTS-c lawful to compound. The panel vote is advisory and formal rulemaking could take more than a year.
Source: FDA Law Blog, Apr 2026
Charles Snow and Karla PalmerSourceMixed view
Money: Law firm advises compounders and industry
Reported the panel backed MOTS-c for obesity and osteoporosis uses, while noting FDA reviewers could not find enough evidence to judge effectiveness and that the vote still needs FDA sign-off.
American Med Spa AssociationSourceMixed view
Money: Represents clinics that sell peptide treatments
Reported that WADA put semaglutide on the monitoring program from 2024 to measure use in sport, without banning it. The same update added MOTS-c to the banned list as an unapproved weight-loss peptide.
Source: USADA athlete advisory, 2023-10
Told the public not to inject peptides bought online. Said unauthorized products are illegal, unproven and may cause organ damage, clots or tumour growth. A research-use-only label does not make them legal.
Source: Health Canada advisory, 2026-04
Health CanadaSourceWarns against
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
FDA advisers vote to ease peptide restrictions, despite agency concerns
Will Stone, NPR
Reports an FDA advisory panel's narrow vote to let compounders make gray-market peptides including MOTS-c, despite staff warnings about thin human data and cancer worries.
Best single account of where MOTS-c stands with regulators.
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
Lizzy Lawrence and Sarah Todd, STAT reporters
Details the panel's votes, with MOTS-c backed 7-5, while noting FDA staff saw too little evidence and most yes voters had peptide industry ties.
Shows the conflicts of interest behind the vote.
FDA Panel Clears the Way for 6 Banned Peptides. Here's What They're Claimed to Do
Ed Cara, Gizmodo reporter
Plain summary of the peptides the panel reviewed, describing MOTS-c as a possible exercise-effect mimic studied for obesity and diabetes, with claims still unproven.
Quick guide to what each peptide is claimed to do.
How does the MOTS-c Peptide Work?
Dr Rob Swanda, science educator
A science educator explains what MOTS-c is and how this mitochondria-derived peptide is thought to work in the body.
Mechanism explainer from a non-seller educational channel.
When options run out
Uses people turn to when standard treatment has failed.
Compounded use for obesity and osteoporosis
- Who
- Clinic patients seeking metabolic or bone benefits outside approved drugs. These were the uses the FDA panel reviewed in 2026.
- Evidence
- FDA reviewers found too little evidence to assess effectiveness for either condition. USADA says no human clinical trials have been completed.
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Questions people ask
Does MOTS-c work in humans?
Nobody knows. In mice it improves how muscle handles sugar and mimics some effects of exercise, but no human trial of MOTS-c itself has been published.
Does MOTS-c help with fat loss?
There is no human evidence. A related compound, CB4211, was tried for four weeks in 20 people with fatty liver: liver enzymes and glucose fell a little, but liver fat did no better than placebo.
Is MOTS-c safe?
There are no human safety data for MOTS-c. FDA cites the risk of immune reactions to injected peptide and its impurities, and the related compound caused injection-site reactions in over 10% of people.
Is MOTS-c legal in the US?
FDA advisers voted 7 to 5 in July 2026 to allow compounding, but FDA staff opposed it and FDA had not acted by late September 2026.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- FDA: bulk substances that may present significant safety risks
- CohBar: CB4211 phase 1a/1b results
- McDermott: July 2026 advisory committee votes
- WADA Prohibited List
Structure: PubChem